Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Emily Hayes
Hopes for a precision approach for the vast cardiovascular disease population live on – past failed studies of HDL-raising drugs and lack of evidence for genetic typing in Merck's latest analysis of anacetrapib in REVEAL.
Data may pave way for inclusion in heart disease treatment guidelines, ACC spokesperson says.
The addressable patient population in the US could increase by 4.5m if new trial is successful.
Spruce's competing drug with same mechanism of action is also in Phase II, with data expected at the end of March.
The PD-L1 inhibitor is the first checkpoint immunotherapy to gain approval in the tough-to-treat disease setting.
Emerging Company Profile: Spruce and Neurocrine are both testing CRF-R1 antagonists for the orphan disease congenital adrenal hyperplasia, with Phase II data coming soon.